Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that drugs of the SGLT2i class, such as empagliflozin, canagliflozin, and dapagliflozin, have pleiotropic effects in preventin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenghong, Ma, Xiaoxuan, Ilyas, Iqra, Zheng, Xueying, Luo, Sihui, Little, Peter J., Kamato, Danielle, Sahebkar, Amirhossein, Wu, Weiming, Weng, Jianping, Xu, Suowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977463/
https://www.ncbi.nlm.nih.gov/pubmed/33754074
http://dx.doi.org/10.7150/thno.54498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977463/
https://www.ncbi.nlm.nih.gov/pubmed/33754074
http://dx.doi.org/10.7150/thno.54498

Ejemplares similares